Mutations in a gene essential for cell regulation cause kidney cancer in children
Mutations in a gene that helps regulate when genes are switched on and off in cells have been found to cause rare cases of Wilms tumor, the most common kidney cancer occurring in children. A study identified mutations in the CTR9 gene in six children with Wilms tumour.
Wilms tumor affects approximately 1 in 10,000 children and usually develops before age 5 years. Treatment of Wilms tumor is very successful, with 90% of children achieving a cure.
Usually Wilms tumor only affects one child in a family, but very rarely more than one child in a family develops the cancer. When this happens, a likely involvement of hereditary genetic factors is indicated.
The researchers studied the genes of 35 families with more than one case of Wilms tumor, recruited to the study through a network of collaborators from across the world. In six children, from three different families, they found CTR9 mutations that stopped the gene working properly. No similar mutations were present in 1,000 persons without Wilms tumor.
The research, led by scientists at The Institute of Cancer Research, London, United Kingdom, was published in Nature Communications (2014; doi:10.1038/ncomms5398). It is part of the Factors Associated with Childhood Tumours Study, which is funded by the Wellcome Trust, and aims to identify genetic causes of childhood cancers. The study was also supported by Cancer Research UK.
CTR9 is part of a multiprotein complex, known as PAF1, which regulates when genes are switched on and off. The PAF1 complex has many essential diverse roles in controlling cellular processes and organ development in the embryo. Interestingly, mutations of another gene in the complex, CDC73, have previously been shown to cause cancer, particularly of the parathyroid gland, but also occasionally Wilms tumor.
"This research adds further evidence that malfunctioning of the PAF1 complex can lead to cancer. We hope our findings will stimulate research into why and how this occurs and will lead to improved treatments for cancer,” said study leader Nazneen Rahman, PhD, Head of Genetics and Epidemiology at The Institute of Cancer Research, London, and Head of Cancer Genetics at The Royal Marsden NHS Foundation Trust.
Rahman added, “Our findings are also of immediate value to affected families, who now have an explanation for why their children got cancer. Moreover, we can now do a simple blood test to see which children in the family are at risk of cancer and may benefit from cancer screening, and which have not inherited the mutation and so are not at increased risk of cancer."